scholarly journals Oxidative alterations in sickle cell disease: Possible involvement in disease pathogenesis

2017 ◽  
Vol 6 (3) ◽  
pp. 55 ◽  
Author(s):  
Yesim Oztas ◽  
Ahmet Yalcinkaya
2017 ◽  
Vol 9 (1) ◽  
pp. e2017015 ◽  
Author(s):  
Giovanna Cannas ◽  
Solene Poutrel ◽  
Xavier Thomas

While hydroxycarbamine (hydroxyurea, HU) has less and less indications in malignant hemopathies, it represents the only widely used drug which modifies sickle cell disease pathogenesis. Clinical experience with HU for patients with sickle cell disease has been accumulated over the past 25 years in Western countries. The review of the literature provides increasing support of safety and efficacy in both children and adults for reducing acute vaso-occlusive events including pain episodes and acute chest syndrome. HU has become the standard-of-care for sickle cell anemia, but remains underused. Barriers to its use should be identified and overcome.


2020 ◽  
Vol 224 ◽  
pp. 1-11 ◽  
Author(s):  
Júlia Teixeira Cottas de Azevedo ◽  
Kelen Cristina Ribeiro Malmegrim

1974 ◽  
Vol 133 (4) ◽  
pp. 624-631 ◽  
Author(s):  
T. A. Bensinger

1974 ◽  
Vol 134 (1) ◽  
pp. 181a-181
Author(s):  
D. C. Salyer

2020 ◽  
Vol 8 (4) ◽  
pp. 390-401 ◽  
Author(s):  
Taryn M. Allen ◽  
Lindsay M. Anderson ◽  
Samuel M. Brotkin ◽  
Jennifer A. Rothman ◽  
Melanie J. Bonner

Sign in / Sign up

Export Citation Format

Share Document